Future studies should assess larger patient cohorts to determine the clinical utility of using CYP2S1 and CYP2W1 as biomarkers, including examining their role in the hormonal and chemotherapeutic response of breast cancer patients. This evidence concerns the gene CYP2S1 and breast cancer.